Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) (State or oth ...

[PART I – Financial Information](index=4&type=section&id=PART%20I%20%E2%80%93%20Financial%20Information) This section presents the company's unaudited condensed consolidated financial statements for the quarter ended March 31, 2021 [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for the quarter ended March 31, 2021, detailing financial position, performance, and cash flows [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section provides a snapshot of the company's financial position at specific points in time, detailing assets, liabilities, and equity Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $43,454 | $34,690 | | Total current assets | $62,235 | $54,112 | | Goodwill | $61,614 | $57,255 | | Total assets | $146,878 | $133,423 | | **Liabilities and Shareholders' Equity** | | | | Total current liabilities | $36,938 | $31,681 | | Total liabilities | $73,628 | $69,108 | | Total shareholders' equity | $73,250 | $64,315 | | Total liabilities and shareholders' equity | $146,878 | $133,423 | [Condensed Consolidated Statements of Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income) This section details the company's financial performance over a period, showing revenues, expenses, and net income Condensed Consolidated Statements of Income (in thousands, except per share data) | Metric | Three months ended March 31, 2021 | Three months ended March 31, 2020 | | :--- | :--- | :--- | | Revenue | $35,464 | $33,860 | | Total operating expenses | $23,444 | $22,666 | | Operating income | $12,020 | $11,194 | | Net income | $9,232 | $11,755 | | Basic Earnings Per Share | $0.36 | $0.47 | | Diluted Earnings Per Share | $0.36 | $0.46 | [Condensed Consolidated Statements of Comprehensive Income](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Income) This section presents net income and other comprehensive income items, reflecting all changes in equity from non-owner sources Condensed Consolidated Statements of Comprehensive Income (in thousands) | Metric | Three months ended March 31, 2021 | Three months ended March 31, 2020 | | :--- | :--- | :--- | | Net income | $9,232 | $11,755 | | Foreign currency translation adjustment | $56 | $(1,124) | | Comprehensive income | $9,288 | $10,631 | [Condensed Consolidated Statements of Shareholders' Equity](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Shareholders'%20Equity) This section details changes in the company's equity accounts, including net income, share repurchases, and other equity transactions - Total shareholders' equity increased from **$64.3 million** at December 31, 2020, to **$73.3 million** at March 31, 2021, primarily driven by net income of **$9.2 million**[20](index=20&type=chunk) - During the three months ended March 31, 2021, the company purchased **26,932 shares** of treasury stock for **$1.21 million**[20](index=20&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section reports the cash generated and used by the company across operating, investing, and financing activities Condensed Consolidated Statements of Cash Flows (in thousands) | Cash Flow Activity | Three months ended March 31, 2021 | Three months ended March 31, 2020 | | :--- | :--- | :--- | | Net cash provided by operating activities | $14,408 | $5,523 | | Net cash used in investing activities | $(4,238) | $(590) | | Net cash used in financing activities | $(1,429) | $(7,536) | | Change in cash and cash equivalents | $8,764 | $(3,496) | | Cash and cash equivalents at end of period | $43,454 | $10,021 | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section provides additional details and explanations for the figures presented in the financial statements - In March 2021, the company changed its operating segments from six to one to reflect a change in corporate reporting structure[27](index=27&type=chunk) - On January 4, 2021, the company acquired substantially all assets of PatientWisdom, Inc. for a total consideration of **$5.0 million** in cash, adding a health engagement solution to its portfolio[56](index=56&type=chunk) - The effective tax rate for Q1 2021 was a **20.5% expense**, a significant increase from the **3.4% benefit** in Q1 2020, mainly due to decreased tax benefits from share-based compensation awards and higher state income taxes[62](index=62&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial performance, liquidity, and capital resources for Q1 2021, highlighting revenue growth and operational changes [Results of Operations](index=24&type=section&id=Results%20of%20Operations) This section analyzes the company's revenue, operating expenses, and profitability for the period, explaining key drivers of change Revenue and Operating Income Comparison (in millions) | Metric | Q1 2021 | Q1 2020 | % Change | | :--- | :--- | :--- | :--- | | Revenue | $35.5 | $33.9 | +4.7% | | Operating Income | $12.0 | $11.2 | +7.1% | - Revenue growth was primarily due to new customer sales and increased sales to the existing client base, partially offset by a **$605,000** decrease in conference revenue due to a shift to a virtual format[101](index=101&type=chunk) - Direct expenses decreased by **4.8%** to **$11.9 million**, mainly due to lower postage, printing, and travel costs, despite an increase in contracted services[102](index=102&type=chunk) - Selling, general and administrative (SG&A) expenses increased by **8.8%** to **$9.5 million**, driven by higher software, hosting, and contracted services costs, partially offset by lower travel expenses[103](index=103&type=chunk) [Liquidity and Capital Resources](index=25&type=section&id=Liquidity%20and%20Capital%20Resources) This section assesses the company's ability to meet its short-term and long-term financial obligations and fund its operations - As of March 31, 2021, the company's principal sources of liquidity included **$43.5 million** in cash and cash equivalents, a **$30 million** unused line of credit, and a **$15 million** delayed draw term note[108](index=108&type=chunk) - Working capital increased to **$25.3 million** at March 31, 2021, from **$22.4 million** at December 31, 2020, primarily due to an **$8.8 million** increase in cash and cash equivalents[110](index=110&type=chunk)[111](index=111&type=chunk) Cash Flow Summary (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | Provided by operating activities | $14,408 | $5,523 | | Used in investing activities | $(4,238) | $(590) | | Used in financing activities | $(1,429) | $(7,536) | - The company was in compliance with all financial covenants related to its credit facilities as of March 31, 2021[128](index=128&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=29&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company reports no material changes to its market risk exposures compared to its prior annual report - There are no material changes to the disclosures regarding market risk exposures from the company's 2020 Annual Report on Form 10-K[139](index=139&type=chunk) [Controls and Procedures](index=29&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective, with no material changes to internal controls during the quarter - Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2021[140](index=140&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, the company's internal controls[141](index=141&type=chunk) [PART II – Other Information](index=30&type=section&id=PART%20II%20%E2%80%93%20Other%20Information) This section provides additional disclosures on legal proceedings, risk factors, equity sales, and exhibits [Legal Proceedings](index=30&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in routine legal claims and litigation, with management not expecting a material adverse financial impact - The company is involved in claims and litigation from time to time in the normal course of business, but management does not expect any material adverse effect from the final disposition of current claims[142](index=142&type=chunk) [Risk Factors](index=30&type=section&id=Item%201A.%20Risk%20Factors) This section refers to the significant risk factors detailed in the company's prior annual report that could materially affect its business - For a description of significant risk factors, the report refers to Part I, Item 1A of the company's annual report on Form 10-K for the year ended December 31, 2020[143](index=143&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=31&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company provides an update on its stock repurchase program, noting no repurchases during the quarter and remaining authorized shares - No Common Stock was repurchased under the company's authorization program during the three-month period ended March 31, 2021[145](index=145&type=chunk) - The remaining number of shares of Common Stock that may be purchased under the repurchase authorization is **280,491**[145](index=145&type=chunk) [Exhibits](index=32&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the report, including CEO and CFO certifications and iXBRL financial statements - The exhibits filed with this report include CEO and CFO certifications pursuant to Rule 13a-14(a) and Section 1350, as well as iXBRL formatted financial statements[151](index=151&type=chunk)

PART I [Business](index=3&type=section&id=Item%201.%20Business) NRC Health provides healthcare analytics, focusing on patient and employee experience, with **73.3% of 2020 revenue** from its digital VoC platform - NRC Health provides analytics and insights to help healthcare organizations measure and improve patient and employee experience, engagement, and loyalty[14](index=14&type=chunk) - The company's digital Voice of the Customer (VoC) platform, including Market Insights, Transparency, and Experience solutions, accounted for **73.3% of total revenue in 2020**[21](index=21&type=chunk) - Growth strategy focuses on increasing service scope with existing clients, winning new clients, developing new solutions, and pursuing strategic acquisitions[29](index=29&type=chunk) Revenue from Key Clients and Foreign Customers | Metric | 2020 | 2019 | 2018 | | :--- | :--- | :--- | :--- | | **Revenue from Top 10 Clients** | 14% | 16% | 17% | | **Revenue from Foreign Customers** | 2% | 3% | 4% | - As of December 31, 2020, the company employed **485 associates**, with **13 in Canada**, and the majority operating remotely[52](index=52&type=chunk) [Risk Factors](index=9&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks from the COVID-19 pandemic, contract renewals, intense competition, cybersecurity threats, and founder control - The COVID-19 pandemic presents significant risks, including economic slowdown, reduced demand for clients' elective services, and potential suspension of regulatory survey requirements by CMS[56](index=56&type=chunk)[57](index=57&type=chunk)[59](index=59&type=chunk) - **14% of total revenue in 2020** came from the ten largest clients, making non-renewal a significant risk to operating results[64](index=64&type=chunk) - Cyber-attacks and data security incidents pose risks, as a February 2020 attack led to temporary service suspension, with future incidents potentially causing liability and reputational harm[75](index=75&type=chunk)[76](index=76&type=chunk)[77](index=77&type=chunk) - As of February 26, 2021, trusts and entities controlled by CEO Michael D. Hays' family held approximately **54.0% of outstanding common stock**, granting effective control over shareholder approval matters[86](index=86&type=chunk)[87](index=87&type=chunk) [Unresolved Staff Comments](index=14&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments - There are no unresolved staff comments to report[94](index=94&type=chunk) [Properties](index=15&type=section&id=Item%202.%20Properties) The company owns its Lincoln, Nebraska headquarters and is transitioning to a remote workforce, not renewing most leased office spaces - The company owns its headquarters in Lincoln, Nebraska, covering **62,000 square feet**[96](index=96&type=chunk) - Due to a transition to a remote workforce, the company does not anticipate renewing office leases in Markham, Seattle, and Atlanta upon expiration[97](index=97&type=chunk) [Legal Proceedings](index=15&type=section&id=Item%203.%20Legal%20Proceedings) The company is involved in routine claims and litigation, assessing and recording liabilities for probable and estimable losses - The company is involved in certain claims and litigation arising from the normal course of business, with management assessing and recording liabilities for probable and estimable losses[98](index=98&type=chunk) [Mine Safety Disclosures](index=15&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[99](index=99&type=chunk) PART II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=16&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on NASDAQ under "NRC," with a 2018 recapitalization eliminating Class B stock, and a stock repurchase program in place - In April 2018, a recapitalization exchanged Class B common stock for Class A common stock plus **$19.59 in cash**, eliminating Class B stock and reclassifying Class A as Common Stock (NRC)[103](index=103&type=chunk) Dividends Declared & Paid | Year | Dividends Declared & Paid (in millions) | | :--- | :--- | | **2020** | $5.3 | | **2019** | $19.4 (declared) | | **2018** | $29.7 (declared) | - The stock repurchase program has authorization remaining to purchase **280,491 shares** of Common Stock, with no shares repurchased in Q4 2020[105](index=105&type=chunk) [Selected Financial Data](index=18&type=section&id=Item%206.%20Selected%20Financial%20Data) This section provides a five-year financial summary (2016-2020), showing consistent revenue growth and fluctuating assets due to a 2018 recapitalization Five-Year Financial Summary | (In thousands, except per share data) | 2020 | 2019 | 2018 | 2017 | 2016 | | :--- | :--- | :--- | :--- | :--- | :--- | | **Revenue** | $133,277 | $127,982 | $119,686 | $117,559 | $109,384 | | **Operating income** | $42,677 | $43,035 | $35,275 | $34,219 | $31,197 | | **Net income** | $37,260 | $32,406 | $30,047 | $22,943 | $20,518 | | **Diluted EPS (Common Stock)** | $1.45 | $1.26 | $1.04 | $0.52 | $0.48 | | **Total assets** | $133,423 | $110,685 | $108,032 | $127,316 | $120,624 | | **Total shareholders' equity** | $64,315 | $32,892 | $19,083 | $90,041 | $82,806 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=19&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Revenue increased **4.1% to $133.3 million** in 2020, but operating income slightly decreased due to higher expenses and a goodwill impairment, while liquidity remained strong - The COVID-19 pandemic impacted business with some clients reducing services, and management does not expect recent revenue and earnings growth to be indicative of future performance[118](index=118&type=chunk) - Operating income in 2020 was impacted by a **$1.1 million increase in depreciation and amortization** and a **$714,000 goodwill impairment charge** for the Canadian reporting unit[119](index=119&type=chunk)[128](index=128&type=chunk) Financial Performance Highlights | (In millions) | 2020 | 2019 | | :--- | :--- | :--- | | **Revenue** | $133.3 | $128.0 | | **Operating Income** | $42.7 | $43.0 | | **Net Income** | $37.3 | $32.4 | - As of December 31, 2020, the company had strong liquidity with **$34.7 million in cash and cash equivalents**, a **$30 million unused line of credit**, and a **$15 million delayed draw term note**[148](index=148&type=chunk) [Quantitative and Qualitative Disclosure About Market Risk](index=27&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosure%20About%20Market%20Risk) The company's market risks include foreign currency exposure from its Canadian subsidiary and interest rate risk from its fixed-rate term loan and variable-rate line of credit - A hypothetical **10% change in the USD/CAD exchange rate** would impact the reported cash balance by approximately **$686,000** due to foreign currency risk from the Canadian subsidiary[183](index=183&type=chunk) - Interest rate risk exists for the **$30.7 million fixed-rate Term Loan** and variable-rate Line of Credit, with a **1% change in market rates impacting the fair value of fixed-rate debt by about $944,000**[184](index=184&type=chunk)[185](index=185&type=chunk) - The company acknowledges the expected phase-out of LIBOR in 2021, which affects its variable-rate credit facilities, with the credit agreement allowing for a substitute index[186](index=186&type=chunk) [Financial Statements and Supplementary Data](index=28&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the audited consolidated financial statements for 2020, including the auditor's report, balance sheets, income statements, and detailed notes - KPMG LLP issued an opinion stating the consolidated financial statements are presented fairly and that the company maintained effective internal control over financial reporting as of December 31, 2020[191](index=191&type=chunk) - The auditor identified the evaluation of sufficiency of audit evidence over new and modified subscription-based service agreement terms as a critical audit matter due to subjective judgment in revenue recognition[198](index=198&type=chunk)[200](index=200&type=chunk) Consolidated Balance Sheet Highlights | (In thousands) | Dec 31, 2020 | Dec 31, 2019 | | :--- | :--- | :--- | | **Total Current Assets** | $54,112 | $29,157 | | **Total Assets** | $133,423 | $110,685 | | **Total Current Liabilities** | $31,681 | $38,155 | | **Total Liabilities** | $69,108 | $77,793 | | **Total Shareholders' Equity** | $64,315 | $32,892 | - Subsequent to year-end, on January 4, 2021, the company acquired PatientWisdom, Inc. for **$5.0 million in cash** to enhance its health engagement solutions[319](index=319&type=chunk) [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=55&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) This item is not applicable to the company - Not applicable[321](index=321&type=chunk) [Controls and Procedures](index=55&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management and the independent auditor concluded that the company's disclosure controls and internal control over financial reporting were effective as of December 31, 2020 - Management concluded that the company's disclosure controls and procedures were effective as of December 31, 2020[322](index=322&type=chunk) - Based on the COSO framework, management concluded that the company's internal control over financial reporting was effective as of December 31, 2020[324](index=324&type=chunk) [Other Information](index=55&type=section&id=Item%209B.%20Other%20Information) The company reports no other information to disclose for this item - No other information is reported[327](index=327&type=chunk) PART III [Directors, Executive Officers and Corporate Governance](index=56&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information on directors, executive officers, and corporate governance is incorporated by reference from the 2021 Proxy Statement - Required information regarding directors, executive officers, and corporate governance is incorporated by reference from the 2021 Proxy Statement[330](index=330&type=chunk) [Executive Compensation](index=56&type=section&id=Item%2011.%20Executive%20Compensation) Information regarding executive compensation is incorporated by reference from the company's 2021 Proxy Statement - Required information regarding executive compensation is incorporated by reference from the 2021 Proxy Statement[332](index=332&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters](index=56&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Shareholder%20Matters) Security ownership information is incorporated by reference from the 2021 Proxy Statement, with a table detailing equity compensation plans Equity Compensation Plan Information as of December 31, 2020 | Plan Category | Securities to be Issued Upon Exercise | Weighted-Average Exercise Price | Securities Remaining for Future Issuance | | :--- | :--- | :--- | :--- | | **Equity compensation plans approved by security holders** | 600,571 | $25.31 | 1,610,219 | | **Equity compensation plans not approved by security holders** | -- | -- | -- | | **Total** | **600,571** | **$25.31** | **1,610,219** | [Certain Relationships and Related Transactions, and Director Independence](index=57&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information on related party transactions and director independence is incorporated by reference from the company's 2021 Proxy Statement - Required information regarding certain relationships, related transactions, and director independence is incorporated by reference from the 2021 Proxy Statement[338](index=338&type=chunk) [Principal Accountant Fees and Services](index=57&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Information detailing the principal accountant's fees and services is incorporated by reference from the company's 2021 Proxy Statement - Required information regarding principal accountant fees and services is incorporated by reference from the 2021 Proxy Statement[339](index=339&type=chunk) PART IV [Exhibits, Financial Statement Schedules](index=58&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statement%20Schedules) This section lists all exhibits filed with the Form 10-K, including financial statements, corporate documents, and certifications - This section provides an index of all exhibits filed with the Form 10-K, including corporate governance documents, material contracts, and required certifications[343](index=343&type=chunk) [Form 10-K Summary](index=59&type=section&id=Item%2016.%20Form%2010-K%20Summary) The company indicates that there is no Form 10-K summary - None[346](index=346&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) Wisconsin 47-0634000 (Stat ...

National Research Corporation (NASDAQ:NRC) Q2 2020 Earnings Conference Call August 5, 2020 11:00 AM ET Company Participants Kevin Karas - Chief Financial Officer Conference Call Participants John Lewis - Willis Investment Counsel Operator Greetings and welcome to the Second Quarter 2020 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded, Wednesday, August 5, 2020. I would now like to turn the conference over to Kevin Karas, Chief Financial Officer. Please go ahead. Ke ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ (Address of principal executive offices) (Zip Code) (402) 475-2525 (Registrant's telephone number, including area code) Commission ...

National Research Corporation (NASDAQ:NRC) Q1 2020 Earnings Conference Call May 6, 2020 11:00 AM ET Company Participants Kevin Karas - CFO Conference Call Participants Operator Greetings and welcome to the First Quarter 2020 Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we'll conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference is being recorded Wednesday, May 6, 2020. I would now like to turn the conference ove ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-35929 National Research Corporation (Exact name of Registrant as specified in its charter) (State or ot ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-35929 National Research Corporation (Exact name of registrant as specified in its charter) Wisco ...

National Research Corporation (NASDAQ:NRC) Q4 2019 Earnings Conference Call February 12, 2020 11:00 AM ET Company Participants Michael Hays - Chief Executive Officer Linda Stacy - Vice President, Finance Steve Jackson - President Conference Call Participants Operator Greetings and welcome to the Fourth Quarter 2019 Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we'll conduct a question-and-answer session. [Operator Instructions] And as a reminder, this ...